Back to Market返回行情

MRVI Maravai LifeSciences Holdings, Inc.

USHealthcare
$5.97+3.65%ClosedMarket Cap: $1.65B

As of 2026-07-09 16:00

Why MRVI matters now

Maravai LifeSciences Holdings, Inc. (MRVI) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.97 with +3.65% on the session and $1.65B in market capitalization; recent performance reads 1-month +23.22% and YTD +60.00%.

The latest financial table shown here is Q1 2026, with revenue of $65.8M, net income of $-3.7M, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.6%.

The latest indexable market news headline is "TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale" from GuruFocus.

Additional event context on this page matters because analyst consensus is Hold with a median target of $6.00; recent insider activity includes ORESHACK KURT filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

3.60

P/S

7.02

EV/EBITDA

-14.83

DCF Value

$2.40

FCF Yield

-3.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

29.0%

Operating Margin

21.9%

Net Margin

-51.1%

ROE

-44.7%

ROA

-14.7%

ROIC

6.5%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$65.8M$-3.7M$-0.03
Q4 2025$49.9M$-35.7M$-0.25
FY 2025$185.7M$-130.8M$-0.91
Q3 2025$41.6M$-25.6M$-0.18

Analyst Ratings

Consensus

Hold

Target (Consensus)

$6.00

Target (Median)

$6.00

Target Range

$6.00 - $6.00

Strong Buy: 0Buy: 5Hold: 4Sell: 0Strong Sell: 0
Wells FargoOverweight
2026-05-08
Wells FargoOverweight
2025-12-15
RBC CapitalOutperform
2025-08-12
Craig-HallumBuy
2025-08-12

Trading Activity

Insider Trades

ORESHACK KURTofficer: General Counsel
Sell2026-06-10
LUCIER GREGORY Tdirector
Sell2026-06-10
LUCIER GREGORY Tdirector
Sell2026-06-10
ORESHACK KURTofficer: General Counsel
Sell2026-06-10
Brust Bernddirector, officer: Chief Executive Officer
Sell2026-06-10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.71

Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.